“People first thought of having long-term survivor clinical
programs about 20 years ago primarily because it wasn’t even
until the late 1970s that you started to see an increasing
number of children who were treated for various malignancies
become survivors,” says Stuart Toledano, M.D., who heads the
clinic and is director of the Division of Pediatric Hematology/
Oncology in the Department of Pediatrics at the Miller School of
Medicine. “We started to recognize a unique set of problems and
late effects of their treatment, both medical as well as
psychosocial, in this group of children and young adults who had
survived cancer. And frankly there was no information in the
literature about this group of patients because before long-term
survival was rare. These kids would be the first generation to
survive in large numbers, and they would go on to teach us
everything we know, and their experiences impact how we treat
children diagnosed today with cancer.” The current treatment for
Hodgkin’s disease resulted direc